A Phase 2 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Ovarian Neoplasms, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ovarian Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Ovarian Neoplasms · Sanofi.
Among the 14 studies in Ovarian Neoplasms by Sanofi, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is one of 9 in phase 2, and was the 5th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 14 studies in Ovarian Neoplasms by Sanofi is open now. The open studies under Ovarian Neoplasms, anywhere →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 13 interventional studies, 30 across the 1 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Ovarian Neoplasms by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic malignant ascites.
The secondary objectives were to further assess efficacy and safety of Aflibercept treatment, and the exploratory objectives were to assess pharmacokinetics, immunogenicity and health-related quality of life.
The study consisted of:
During the study, participants were treated with Aflibercept study treatment through the duration of the study unless they met one the following criteria for discontinuation:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants that met the following criteria were eligible.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to participation in a clinical trial.
Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
4.0 mg/kg administered intravenously (IV) once every 2 weeks
Percentage of Participants With a Repeat Paracentesis Response (RPR)
RPR was defined as at least a two-fold increase in the time to repeat paracentesis (TRP) as compared to the average duration of the 2 intervals between the 3 most recent paracenteses prior to study registration (ie, the baseline interval of paracentesis). Percentage of participants with a repeat paracentesis response were the number of participants with RPR / number of total participants \* 100.
Time frame: up to 2 years post-registration
Time to Repeat Paracentesis (TRP)
TRP is the number of days between the date of registration and the date of the first postregistration paracentesis. Median TRP was estimated from Kaplan-Meier curves. For participants who did not undergo a postregistration paracentesis while on study, TRP was censored at the end of the treatment period (last dose + 1 cycle), at the last visit known without repeat paracentesis, at 6 months postregistration, or at death, whichever was earlier.
Time frame: up to 6 months from registration
60-day Frequency of Paracentesis (FOP)
FOP was the total number of paracenteses performed within the first 60 days postregistration. For participants who had withdrawn after registration but prior to the 60-day cutoff date, the withdrawal would have been regarded as a paracentesis event and the 60-day FOP normalized and calculated as the nearest integer of the value corresponding to 60 × number of paracenteses / x, where x represents the number of days on study.
Time frame: up to 60 days post-registration
Progression-free Survival (PFS) Time
According to the Response Evaluation Criteria in Solid Tumors \[RECIST\], progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. PFS time was interval from the date of registration to the date of tumor progression or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. If participants were alive and progression-free at 6 months postregistration, they were censored for PFS.
Time frame: up to 6 months post-registration
Overall Survival (OS) Time
OS time was the time interval between the date of registration to the date of death from any cause. Median OS was estimated from Kaplan-Meier curves. Participants who died after efficacy data cutoff date (6 months postregistration) were censored at the data cutoff date.
Time frame: up to 6 months post-registration
Number of Participants With a Positive Anti-drug Antibody Response
Anti-drug antibodies in participant's serum were measured using 2 different methods * an Enzyme Linked Immunosorbent Assay (ELISA) in which the lower limit of detection (LLOD) was 238.4 ng/mL; and * an Electrochemiluminescence-based, Bridging Assay in which the validated LLOD was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept. Participants with detectable anti-drug antibodies by either method were considered to have a positive anti-drug antibody response.
Time frame: up to 60 days after the last dose of treatment
Safety - Number of Participants With Adverse Events (AE)
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
Time frame: up to 60 days after last dose of treatment (approximately 2 years), or until TEAE was resolved or stabilized
17 participants were screened for this study, of which 16 participants were enrolled.
| Milestone | Aflibercept |
|---|---|
| Started | 16 |
| Completed | 0 |
| Not completed | 16 |
| Withdrew: Disease progression | 13 |
| Withdrew: Adverse event | 2 |
| Withdrew: Participant request | 1 |
RPR was defined as at least a two-fold increase in the time to repeat paracentesis (TRP) as compared to the average duration of the 2 intervals between the 3 most recent paracenteses prior to study registration (ie, the baseline interval of paracentesis). Percentage of participants with a repeat paracentesis response were the number of participants with RPR / number of total participants \* 100.
| percentage of participants | Aflibercept |
|---|---|
| Percentage of Participants With a Repeat Paracentesis Response (RPR) | 62.5 (35.43 to 84.80) |
TRP is the number of days between the date of registration and the date of the first postregistration paracentesis. Median TRP was estimated from Kaplan-Meier curves. For participants who did not undergo a postregistration paracentesis while on study, TRP was censored at the end of the treatment period (last dose + 1 cycle), at the last visit known without repeat paracentesis, at 6 months postregistration, or at death, whichever was earlier.
| days | Aflibercept |
|---|---|
| Time to Repeat Paracentesis (TRP) | 76.0 (64.0 to 178.0) |
FOP was the total number of paracenteses performed within the first 60 days postregistration. For participants who had withdrawn after registration but prior to the 60-day cutoff date, the withdrawal would have been regarded as a paracentesis event and the 60-day FOP normalized and calculated as the nearest integer of the value corresponding to 60 × number of paracenteses / x, where x represents the number of days on study.
| paracenteses | Aflibercept |
|---|---|
| 60-day Frequency of Paracentesis (FOP) | 1.5 ± 1.6 |
According to the Response Evaluation Criteria in Solid Tumors \[RECIST\], progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. PFS time was interval from the date of registration to the date of tumor progression or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. If participants were alive and progression-free at 6 months postregistration, they were censored for PFS.
| days | Aflibercept |
|---|---|
| Progression-free Survival (PFS) Time | 59.5 (41.0 to 83.0) |
OS time was the time interval between the date of registration to the date of death from any cause. Median OS was estimated from Kaplan-Meier curves. Participants who died after efficacy data cutoff date (6 months postregistration) were censored at the data cutoff date.
| days | Aflibercept |
|---|---|
| Overall Survival (OS) Time | 92.0 (58.0 to NA) |
Anti-drug antibodies in participant's serum were measured using 2 different methods * an Enzyme Linked Immunosorbent Assay (ELISA) in which the lower limit of detection (LLOD) was 238.4 ng/mL; and * an Electrochemiluminescence-based, Bridging Assay in which the validated LLOD was about 5.4 ng/mL in the absence of aflibercept and about 25.2 ng/mL in the presence of 20 μg/mL of aflibercept. Participants with detectable anti-drug antibodies by either method were considered to have a positive anti-drug antibody response.
| participants | Aflibercept |
|---|---|
| Number of Participants With a Positive Anti-drug Antibody Response | 0 |
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
| participants | Aflibercept |
|---|---|
| With at least one TEAE | 16 |
| With at least one serious TEAE | 15 |
| With a TEAE leading to death | 8 |
| With a TEAE resulting in discontinuation | 2 |
Collected over From treatment initiation to January 30, 2009. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept | — | 15/16 (93.8%) | 16/16 (100%) |
| Event | Aflibercept |
|---|---|
| Intestinal obstructionGastrointestinal disorders | 5/16 |
| VomitingGastrointestinal disorders | 4/16 |
| Disease progressionGeneral disorders | 4/16 |
| NauseaGastrointestinal disorders | 2/16 |
| AnaemiaBlood and lymphatic system disorders | 1/16 |
| TachyarrhythmiaCardiac disorders | 1/16 |
| Abdominal painGastrointestinal disorders | 1/16 |
| Intestinal perforationGastrointestinal disorders | 1/16 |
| Large intestinal obstructionGastrointestinal disorders | 1/16 |
| Small intestinal obstructionGastrointestinal disorders | 1/16 |
| Event | Aflibercept |
|---|---|
| VomitingGastrointestinal disorders | 8/16 |
| HypertensionVascular disorders | 7/16 |
| Abdominal painGastrointestinal disorders | 6/16 |
| NauseaGastrointestinal disorders | 6/16 |
| AstheniaGeneral disorders | 5/16 |
| Disease progressionGeneral disorders | 5/16 |
| AnorexiaMetabolism and nutrition disorders | 5/16 |
| FatigueGeneral disorders | 4/16 |
| ConstipationGastrointestinal disorders | 3/16 |
| Oedema peripheralGeneral disorders | 3/16 |
| Age Continuous(years) | Aflibercept |
|---|---|
| Mean | 59.3 ± 8.9 |
| Age, Customized(participants) | Aflibercept |
|---|---|
| <65 years | 11 |
| >=65 years | 5 |
| Sex: Female, Male(Participants) | Aflibercept |
|---|---|
| Female | 16 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Aflibercept |
|---|---|
| Caucasian | 16 |
| Primary tumor site - Ovaries(Participants) | Aflibercept |
|---|---|
| Number | 16 |
| Time since initial cancer diagnosis(Years) | Aflibercept |
|---|---|
| Mean | 2.8 ± 1.7 |
| Histology(Participants) | Aflibercept |
|---|---|
| Serous | 9 |
| Endometrioid | 3 |
| Clear cell (mesonephroid) | 1 |
| Other | 1 |
| Missing data | 2 |
| Histology grade(Participants) | Aflibercept |
|---|---|
| Unknown | 5 |
| Moderately differentiated | 1 |
| Poorly differentiated | 10 |
3 further baseline measures are reported on the registry.
The record gives a start of Oct 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 4 years 2 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept